Respiratory tract infection treatment market

Respiratory Tract Infection Treatment Market, by Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), Cough Suppressant, Nasal Decongestant, and Others), by Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, trends, and Forecast to 2026

Request Free Sample

Aug 2018
CMI2030
157 Pages
Excel & Pdf
Pharmaceutical

Summary

Respiratory Tract Infection Treatment Market – Insights

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia, and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe indication of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, and shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of burden to the society.

Therefore, the development of new drugs with less adverse effects for the treatment of respiratory tract infection is a major concern for manufacturers, as there are many generic players in the market, occupying majority of the market share.

The global respiratory tract infection treatment market was valued at US$ 35.64 Bn in 2017, and is expected to witness a CAGR of 6.5% over the forecast period (2018 – 2026).

Figure 1. Global Respiratory Tract Infection Treatment Market Share Analysis (%), By Product Type

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of respiratory diseases is expected to drive growth of the respiratory tract infection treatment market

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting growth of the respiratory tract infection market.

For instance, according to the Biomed Central Respiratory Research 2016, asthma and chronic obstructive pulmonary disease (COPD) are common chronic obstructive lung disorders characterized by variable airflow limitation and airway hyper responsiveness, affecting over 25 million people in the U.S.

Various organizations, institutions, and agencies are working towards improving the diagnosis and medical care needed to reduce the global burden of respiratory diseases. For instance, the Global Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the World Health Organization (WHO) to control chronic respiratory diseases. The main objective of GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to encourage economies to implement health promotion and CRD prevention policies.

Presence of various drugs in pipeline, which is expected to be launched over the forecast period will also boost the market growth of respiratory tract infection treatment. Some of the drugs in the pipeline include Relenza (GSK), MK7264 (Merck & Co.), Presatovir (Gilead), AZD7594, and PT010 (AstraZeneca).

However, presence of various generic manufacturers and low cost of various drugs including antibiotics in the market may hinder the respiratory tract infection treatment market to some extent during the forecast period.

Respiratory Tract Infection Treatment Market- Regional Analysis

On the basis of region, the global respiratory tract infection treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global respiratory tract infection treatment market over the forecast period, owing to increasing number of hospitalizations and emergency visits associated with acute or life threatening medical problems.

According to the study by Society of Critical Care Medicine 2016, over 5.7 million patients are admitted annually in intensive care units (ICUs) in the U.S. for support of airway, breathing or circulation, and comprehensive management of injury.

Also, according to the Centers for Disease Control and Prevention (CDC), 2017, around 1.7 million emergency department visits with chronic and unspecified bronchitis were registered in the U.S. hospital facilities.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding their business in Asia Pacific region, to maximize their R&D activities, as this region provides better access to patients for clinical trials, with low cost operational efficiencies. Increasing government investments in research and development, patient awareness, improved health care infrastructure and facilities, high disposable income, and prevalence of unhealthy lifestyle are also expected to foster growth of the respiratory tract infection treatment market in the Asia Pacific region.

Figure 2: Global Respiratory Tract Infection Treatment Market Share (%), By Region

Source: Coherent Market Insights Analysis (2018)

Respiratory Tract Infection Treatment Market- Competitive Landscape

Increasing approval of new drugs by the Food and Drug Administration (FDA) is also expected to propel the overall market growth over the forecast period. For instance, in November 2017, the U.S. FDA approved Fasenra (Benralizumab) manufactured by AstraZeneca, a respiratory biologic for patients aged 12 years and older who are suffering from asthma, and with an eosinophilic phenotype.

Key players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

Table of Content

Table of Contents

Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

Market Overview

Report Description

Market Definition and Scope

Executive Summary

Market Snippet, By Drug Class
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities

Global Respiratory Tract Infection Treatment Market, By Drug Class, 2016–2026, (US$ Million)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends

Antibiotics

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Non-Steroidal Anti-Inflammatory Drug (NSAIDS)

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Cough Suppressant

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Nasal Decongestant

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Others

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Global Respiratory Tract Infection Treatment Market, By Disease Indication, 2016–2026, (US$ Million)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends

Upper Respiratory Tract Infection

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Lower Respiratory Tract Infection

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Global Respiratory Tract Infection Treatment Market, By Distribution Channel, 2016–2026, (US$ Million)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends

Hospital Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Retail Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Online Pharmacies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)

Global Respiratory Tract Infection Treatment Market, By Region, 2016–2026, (US$ Million)

Introduction

Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2016–2026
Regional Trends

North America

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

U.S.
Canada

Europe

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

Brazil
Mexico
Argentina
Rest of Latin America

Africa

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

North Africa
Central Africa
South Africa

Middle East

Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Disease Indication, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)

GCC Countries
Israel
Rest of Middle East

Competitive Landscape

Heat Map Analysis
Company Profiles

Abbott Laboratories

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

AstraZeneca, Plc

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Abbvie Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Boehringer Ingelheim GmbH

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Cipla Pharmaceutical Company

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

GlaxoSmithKline Plc

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Pfizer Inc.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Merck & Co.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Novartis AG

Company Overview
Product Portfolio
Financial Performance
Recent Highlights

F. Hoffman La Roche Ltd

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Teva Pharmaceutical Industries Ltd.

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Sanofi

Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Analyst Views

Section

References
Research Methodology
About us and Sales Contact

*Browse 25 market data tables and 22 figures on "Respiratory Tract Infection Treatment Market” - Global forecast to 2026”

N/A

- Frequently Asked Questions -

What are the growth estimates for respiratory tract infection treatment market till 2026?

The global respiratory tract infection treatment market is estimated to surpass US$ 62.31 Billion by 2026

Which are the prominent respiratory tract infection treatment market players across the globe?

Major players operating in the global respiratory tract infection treatment market include Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd.

What are the key factors hampering growth of the respiratory tract infection treatment market?

Presence of various generic manufacturers and low cost of various drugs including antibiotics are some of the major factors that are expected to hamper growth of the market over the forecast period.

What are the key factors driving growth of the respiratory tract infection treatment market?

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are some of the major factors that are expected to propel growth of the market over the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the respiratory tract infection treatment market for next 8 years?

The global respiratory tract infection treatment market is estimated to exhibit a CAGR of 6.5% over the forecast period.

Which region is dominating the respiratory tract infection treatment market growth?

Among regions, North America is expected to hold dominant position in the global respiratory tract infection treatment market over the forecast period.